Pharmaceutical compositions for treating and/or preventing CNS disorders

US6624173B1 · kind B1 · utility

Assignee

• Targacept, Inc. · US

Inventors

• Peter A. Crooks · Lexington, US
• Gary Maurice Dull · Lewisville, US
• William Scott Caldwell · Winston-Salem, US
• Balwinder Singh Bhatti · Winston-Salem, US
• Niranjan Madhukar Deo · Cincinnati, US
• Alain Ravard · Lexington, US

Key dates

• Filing date: Jun 30, 1997
• Grant date: Sep 23, 2003
• Expiry date: Aug 1, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo [2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.